AptarGroup, Inc. engages in the design, manufacture, drug delivery, consumer product dispensing, sealing and active packaging solutions, and services for the prescription drug, consumer health care, injectable, active packaging, beauty, personal care, home care, and food and beverages industries. It operates through the following segments: Pharma, Beauty and Home, and Food and Beverage. The company was founded in 1940 and is headquartered in Crystal Lake, IL.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- AptarGroup and Massachusetts General Hospital signed a research collaboration to build an integrated translational platform for nose-to-brain drug delivery. - The platform will combine in vitro, in vivo and computational methods to characterize transport mechanisms, pathways and kinetics across molecular classes. - The intended output is a New Approach Methodology (NAM) aligned with FDA support for human-relevant in vitro and in silico drug development tools. - The work is led by Alice Stanton, PhD, and will incorporate Aptar's Cerespray and Neurospray nasal delivery platforms backed by 30 years of field data.
- AptarGroup announces the first commercial launch of NeoDropper Autoload, an innovative auto-loading dosing dropper technology for prestige skincare and dermocosmetic brands. - The technology features a twist-and-push dispensing mechanism with an auto-loading cap that automatically delivers a consistent dose after each use, improving hygiene and minimizing formula waste. - Dermalogica selected NeoDropper Autoload for its FutureCode Booster serum, with consumers reporting positive feedback on dispensing performance, ease of use, and overall user experience. - The launch builds on a longstanding collaboration between Aptar and Dermalogica, which previously adopted Aptar's fully recyclable mono-material Future dispensing pump in 2022.
- AptarGroup's proprietary nasal delivery system is being utilized in LTR Pharma's Phase II clinical study of SPONTAN, an investigational intranasal spray for erectile dysfunction treatment. - The Phase II study is evaluating the safety, tolerability and pharmacokinetic profile of the rapid-acting intranasal spray, with first patients already dosed. - Aptar Pharma's multidose delivery system provides accurate and consistent dosing throughout clinical development, supported by formulation optimization and human factors expertise. - The collaboration reinforces Aptar Pharma's position as a trusted partner in advancing complex intranasal therapies through robust delivery platforms and regulatory expertise.
- Aptar's LuerVax® and Spray Divider™ nasal delivery systems are being utilized in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate. - The Phase II study will evaluate safety, tolerability, and immune response in approximately 200 U.S. adults, comparing the intranasal vaccine to FDA-approved injectable mRNA vaccines. - The collaboration highlights Aptar's position as a leader in nasal vaccine delivery systems and demonstrates the potential for mucosal immunity through intranasal vaccination approaches.
- AptarGroup has acquired Sommaplast, a Brazilian company specializing in oral dosing pharmaceutical packaging solutions including closures, droppers, dispensers and dosing cups. - The acquisition strengthens Aptar's 25-year presence in Brazil and positions the company to capitalize on the country's fast-growing oral dosing, over-the-counter and nutraceutical markets. - Sommaplast operates from São Paulo with over 400 employees and brings strong customer relationships and dosing expertise to complement Aptar's existing four Brazilian manufacturing facilities.
- Nasus Pharma has executed comprehensive agreements with Aptar, a leading global drug delivery systems manufacturer, to support NS002's clinical development and commercialization pathway. - The collaboration provides Nasus with access to Aptar's commercially proven Unit Dose System technology and established regulatory pathways for both FDA and EMA submissions. - NS002 is being developed as a needle-free intranasal powder epinephrine alternative to autoinjectors for anaphylaxis patients, utilizing Nasus's proprietary powder-based intranasal technology. - The strategic partnership aims to accelerate NS002's path to market while reducing development risks through validated dosing infrastructure and manufacturing capabilities.
- AptarGroup has developed a breakthrough dual-active material science technology that simultaneously controls moisture and oxygen to protect sensitive pharmaceutical formulations. - The technology extends Aptar CSP Technologies' 3-Phase Activ-Polymer™ technology to address degradation challenges in oral solid dose GLP-1 drugs and various medical devices. - This singular solution helps pharmaceutical companies meet strict ICH stability requirements while maintaining drug efficacy, safety, and shelf life for sensitive formulations. - The customizable technology supports products from early R&D through commercial launch and can be applied to multiple platforms including implantable devices and transdermal systems.
- Aptar's clinical study aims to validate its SmartTrack™ platform as an in-vitro-in-silico alternative to comparative clinical endpoint studies for generic inhaled drug products, potentially eliminating a major regulatory hurdle. - The study, beginning Q2 2025, will radio-label three commercial pressurized metered-dose inhalers to compare actual lung deposition with computational predictions, collaborating with Fluidda, Medimprove, and i2c Pharmaceutical Services. - Results will be submitted to the FDA as a Model Master File, allowing multiple pharmaceutical companies to leverage the data when partnering with Aptar, potentially accelerating generic inhaler approvals and expanding patient access.
- Aptar's N-Sorb, utilizing the 3-Phase Activ-Polymer™ platform, has been accepted into the FDA's Emerging Technology Program, signaling a significant advancement in pharmaceutical safety. - N-Sorb addresses N-nitrosamine impurities in drugs, classified as probable human carcinogens, by integrating into packaging to react with precursors and scavenge impurities. - This active packaging intervention could eliminate the need for drug reformulation, supporting compliance with FDA and EMA regulations and potentially accelerating drug development. - The FDA's selective program acceptance highlights N-Sorb's promise in modernizing pharmaceutical manufacturing and quality control, offering a potential pathway for expedited regulatory review.
